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It is a well-known statement of statistical wisdom that all treatments differ.1 We could 
substitute the word ‘intervention’ or the phrase ‘surgical procedure’ for ‘treatment’ and 
qualify the word ‘differ’ by, for instance, saying “have different outcomes”. Yet, in doing so 
we challenge far more than semantics, questioning the relevance of much of the research 
reported in The Bone & Joint Journal, and the wider medical literature. For example, the 
DRAFFT study2-4 compared the clinical effectiveness of Kirschner wire fixation with locking 
plate fixation for patients with a dorsally displaced fracture of the distal radius. Selectively 
picking out the key result of the paper one would conclude that there was no difference in 
outcomes between the two groups; thus that there was no difference between the treatments. 
This result seems to contradict the first statement in this paragraph, which follows from the 
simple argument that by definition all treatments must be different because no two things can 
ever be exactly the same in every respect. This sounds like a matter of philosophical interest 
only, but understanding how we reconcile this apparent contradiction helps shed light on an 
issue that continues to be a cause of confusion for many authors submitting papers to our 
Journal.  
The arguments we use when formulating, testing, reporting and, particularly, interpreting the 
results of statistical analyses, are widely misunderstood but crucial to understanding much 
published clinical research. When reporting the results of studies which compare outcomes 
between treatment groups or experimental units, we almost always test for a significant 
difference between groups using a statistical test that conveniently provides a p-value to aid 
interpretation. The ubiquitous p-value cut-off of 0.05 allows us to classify all results as either 
significant or non-significant. This objective criterion, which we call statistical significance, 
has proved to be simple and effective, despite much criticism.5 However, a fundamental 
aspect of this methodology is that the smallest imaginable difference between treatment 
groups can be shown to be statistically significantly different simply by increasing the sample 
size, typically the number of subjects in the study. As we increase the sample size we get 
progressively more precise estimates of measures such as the mean, so eventually we find 
that, however small the difference is between means, it will be deemed to be statistically 
significantly different. So we can always show, if we are prepared to collect enough data, that 
any treatments we test must be different as we can always, in principle, provide evidence of 
statistical significance; i.e. all treatments differ. Clearly such small differences are likely to be 
of no clinical importance; therefore, evidence to support a statistically significant difference 
does not necessarily imply that the difference is clinically important. 
In order to both plan and interpret the results of all clinical research, we must use the concept 
of a minimum clinically important difference (MCID); sometimes referred to as minimum 
important difference (MID). This is the magnitude of difference, or change, in outcome that 
is considered to be important, either beneficial or harmful, or relevant to the patient, that 
would lead the patient or clinician to consider a change in treatment. By relating all reported 
differences in treatment to the MCID, we are able to differentiate between clinical 
significance and statistical significance. The latter does not always imply the former, but the 
former requires evidence of the latter for us to believe in its veracity. 
Returning to the report of the DRAFFT study, a careful reading shows that the authors are 
clear that “…as the confidence intervals exclude the minimum clinically important 
difference…we conclude that any difference…between treatment groups is unlikely to be 
important to patients…”.2 Because the estimated effect size was smaller than the MCID for 
the primary outcome measure, and the confidence interval also excluded the MCID, the 
conclusion was that the difference between treatment groups was not clinically important. If 
the study sample size had been doubled or trebled, we may well have found evidence of 
statistical significance, but, all other things being equal, we would still have concluded that 
the differences were too small to be clinically important. This explains why the MCID for a 
selected outcome measure is crucial in the design of much clinical research and, in particular, 
randomised controlled trials (RCTs). When undertaking a power analysis before starting an 
RCT, a key determinant of the sample size is the MCID. Research studies are typically 
powered to detect effects that are as small as the MCID, but no smaller, with high probability. 
This helps to moderate or limit the sample size so that we do not waste resources collecting 
such a quantity of data that we can estimate tiny effects, which are of no clinical importance, 
with high precision. 
How do we determine the MCID for an outcome measure? For familiar (hard) outcomes such 
as weight or blood pressure, we can all naturally at least approximate the likely range of the 
MCID; e.g. an improved weight loss for a new dieting intervention, against a standard, of 5 
kg would clearly be clinically important, whereas a change of 10 g would be unimportant. 
However, the definition of a MCID is generally more problematic for patient-reported 
outcome measures (PROMs) such as function, quality of life or pain. Briefly, there are two 
main approaches to determine MCIDs for PROMs:6 anchor-based, or distribution- based 
methods. Anchor-based methods compare the change in a PROM score to another external 
measure of change, the anchor. Most commonly this anchor is another subjective assessment 
by which the patient, for instance, rates their condition as much better, better, unchanged, 
worse, or much worse. Distribution-based methods compare the change in a PROM to a 
measure of variability such as an effect size or standard deviation (SD). The one-half SD 
method considers that a patient improving by more than one-half of the SD of an outcome 
measure has achieved a MCID. For many important and widely used PROMs such as the 
Oxford Hip Score (OHS) and Oxford Knee Score (OKS), MCIDs are well established and 
widely accepted.7 
Authors submitting manuscripts to The Bone & Joint Journal must be precise in how they 
report significance and distinguish between clinical and statistical significance when drawing 
conclusions. It is not always sufficient simply to answer the question “are the treatments 
different?” based on p-values and evidence of statistical significance. If the answer to this 
question is “yes”, then one must always follow-up by asking “how different?”; before 
proceeding to report confidence intervals and to compare estimated effect sizes to the MCID 
– only then can we truly understand and assess the importance of the research. 
 
References: 
1. Nester MR. An applied statistician’s creed. Appl Stat 1996;45:401–410. 
2. Costa ML, Achten J, Parsons NR, et al. Percutaneous fixation with Kirschner wires versus volar 
locking plate fixation in adults with dorsally displaced fracture of distal radius: randomised controlled 
trial. BMJ 2014;349:4807. 
3. Tubeuf S, Yu G, Achten J, et al. Cost effectiveness of treatment with percutaneous Kirschner wires 
versus volar locking plate for adult patients with a dorsally displaced fracture of the distal radius: 
analysis from the DRAFFT trial. Bone Joint J 2015;97-B:1082–1089. 
4. Costa ML, Jameson SS, Reed MR. Do large pragmatic randomised trials change clinical practice?: 
assessing the impact of the Distal Radius Acute Fracture Fixation Trial (DRAFFT). Bone Joint J 
2016;98-B:410–413. 
5. Wasserstein RL, Lazar NA. The ASA’s Statement on p-Values: Context, Process, and Purpose. Am 
Stat 2016;70:129–133. 
6. Copay AG, Subach BR, Glassman SD, Polly DW Jr, Schuler TC. Understanding the minimum 
clinically important difference: a review of concepts and methods. Spine J 2007;7:541–546. 
7. Beard DJ, Harris K, Dawson J, et al. Meaningful changes for the Oxford hip and knee scores after 
joint replacement surgery. J Clin Epidemiol 2015;68:73–79. 
 
Affiliations: 
(1) University of Warwick, 
Statistics and Epidemiology, 
Warwick Medical School, 
Coventry CV4 7AL, UK. 
(2) University of Liverpool, 
Institute of Translational 
Medicine, Easton Rd, Liverpool 
L12 2AP, UK. 
(3) University of Oxford, 
NDORMS, Oxford Trauma, 
Kadoorie Centre, John Radcliffe 
Hospital, Oxford, OX3 7UD, UK. 
 
